Log in

Relevant bibliographies by topics / Antineoplastic agents / Journal articles

To see the other types of publications on this topic, follow the link: Antineoplastic agents.

Journal articles on the topic 'Antineoplastic agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antineoplastic agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Carlson, Patricia A. "Antineoplastic agents." Critical Care Nursing Quarterly 18, no. 4 (1996): 1–15. http://dx.doi.org/10.1097/00002727-199602000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Menta, Ernesto, and Manlio Palumbo. "Novel antineoplastic agents." Expert Opinion on Therapeutic Patents 7, no. 12 (1997): 1401–26. http://dx.doi.org/10.1517/13543776.7.12.1401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Menta, Ernesto, and Manlio Palumbo. "Antineoplastic agents 1998." Expert Opinion on Therapeutic Patents 8, no. 12 (1998): 1627–72. http://dx.doi.org/10.1517/13543776.8.12.1627.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Pettit, G. R., Y. Kamano, R. Aoyagi, et al. "Antineoplastic agents 100." Tetrahedron 41, no. 6 (1985): 985–94. http://dx.doi.org/10.1016/s0040-4020(01)96466-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bukowski, Ronald M. "Novel antineoplastic agents." Current Oncology Reports 2, no. 1 (2000): 9–10. http://dx.doi.org/10.1007/s11912-000-0004-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hong, Samuel J., Edward C. Li, Linda M. Matusiak, and Glen T. Schumock. "Spending on Antineoplastic Agents in the United States, 2011 to 2016." Journal of Oncology Practice 14, no. 11 (2018): e683-e691. http://dx.doi.org/10.1200/jop.18.00069.

Full text

Abstract:

Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative of the whole US health care system or by sector. Therefore, the objective of this study was to describe antineoplastic expenditures in the United States by year and sector. Methods: This was a retrospective, cross-sectional study of IQVIA (formerly QuintilesIMS) National Sales Perspective data for the period of Jan

APA, Harvard, Vancouver, ISO, and other styles

7

DOLL, DONALD C., Q. SCOT RINGENBERG, and JOHN W. YARBRO. "Antineoplastic Agents and Pregnancy." Obstetrical & Gynecological Survey 45, no. 6 (1990): 376. http://dx.doi.org/10.1097/00006254-199006000-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 605. Isoquinstatins." Journal of Natural Products 81, no. 3 (2017): 451–57. http://dx.doi.org/10.1021/acs.jnatprod.7b00352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hussain, M. A. ha, A. N. toinette J. Wozniak, and M. A. rk B. Edelstein. "Neurotoxicity of antineoplastic agents." Critical Reviews in Oncology/Hematology 14, no. 1 (1993): 61–75. http://dx.doi.org/10.1016/1040-8428(93)90006-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Castells, M. "Hypersensitivity to Antineoplastic Agents." Current Pharmaceutical Design 14, no. 27 (2008): 2892–901. http://dx.doi.org/10.2174/138161208786369803.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Fernandez, F. "Psychotoxicity from antineoplastic agents." Journal of Clinical Oncology 5, no. 2 (1987): 319–20. http://dx.doi.org/10.1200/jco.1987.5.2.319.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

McNabb, Lorna, Eva Metrot, Micaela Ferrington, et al. "Assessment of patient perceptions of counselling on oral antineoplastic agents by a dedicated cancer services pharmacist in an outpatient cancer clinic." PLOS ONE 19, no. 6 (2024): e0304011. http://dx.doi.org/10.1371/journal.pone.0304011.

Full text

Abstract:

Background Oral antineoplastic agents have caused a paradigm shift in cancer treatment, however, they produce many unique challenges. Although oral antineoplastics can have complex administration regimes, low adherence rates and high possibilities of drug-drug interactions, they are administered unsupervised at home. Cancer services pharmacists have the required skillsets to improve patient outcomes associated with oral antineoplastic treatment by increasing patient health literacy, improving concordance and optimising administration protocols. Aim To evaluate patients’ perceptions, experience

APA, Harvard, Vancouver, ISO, and other styles

13

Melamed, Andra J., and Michael L. Kleinberg. "Handling Considerations for Cancer Chemotherapeutic Agents." Drug Intelligence & Clinical Pharmacy 22, no. 3 (1988): 247–51. http://dx.doi.org/10.1177/106002808802200317.

Full text

Abstract:

Since the introduction of antineoplastic agents in the 1940s, there have been reports of the effects of these agents on workers who have had prolonged contact with them. The Regional Oncology Drug Information Center (RODIC) at Memorial Sloan-Kettering Cancer Center receives numerous inquiries nationwide regarding our policies and procedures for handling antineoplastic agents. In August 1987, RODIC conducted a computerized literature search on the handling of antineoplastic agents and the risks to hospital employees coming in contact with these agents. We used the MEDLINE system from 1966 to th

APA, Harvard, Vancouver, ISO, and other styles

14

Yamashiro, Yoshiko, Yoshikazu Fukuoka, Akira Yotsuji, Takashi Yasuda, Isamu Saikawa, and Yasushi Ueda. "Interactions of antimicrobial agents and antineoplastic agents." Journal of Antimicrobial Chemotherapy 18, no. 6 (1986): 703–8. http://dx.doi.org/10.1093/jac/18.6.703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Garcia, Gwenalyn, and Jean Paul Atallah. "Antineoplastic agents and thrombotic microangiopathy." Journal of Oncology Pharmacy Practice 23, no. 2 (2016): 135–42. http://dx.doi.org/10.1177/1078155216628324.

Full text

Abstract:

Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.

APA, Harvard, Vancouver, ISO, and other styles

16

Sutton, Karen, Tara B. Sanft, Tish M. Knobf, and Izuchukwu K. Ibe. "Musculoskeletal Effects of Antineoplastic Agents." Journal of the American Academy of Orthopaedic Surgeons 27, no. 22 (2019): 834–39. http://dx.doi.org/10.5435/jaaos-d-17-00713.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

PATTERSON, WILLIAM B. "Occupational Hazard from Antineoplastic Agents." Annals of Internal Medicine 103, no. 6_Part_1 (1985): 965. http://dx.doi.org/10.7326/0003-4819-103-6-965_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Graeve, Catherine Utecht, Patricia Marie McGovern, Bruce Alexander, Timothy Church, Andrew Ryan, and Martha Polovich. "Occupational Exposure to Antineoplastic Agents." Workplace Health & Safety 65, no. 1 (2016): 9–20. http://dx.doi.org/10.1177/2165079916662660.

Full text

Abstract:

Approximately 8 million health care workers are unnecessarily exposed to highly toxic drugs used to treat cancer; antineoplastic drugs can contribute to negative health effects for these workers. The drugs have been detected in the urine of workers and on the floors and counters of worksites. Safety precautions that could reduce the risk of exposure are underutilized. This cross-sectional study of 163 oncology health care workers used a survey to measure workplace and individual factors, and environmental sampling to measure surface contamination. The study objective was to identify potential

APA, Harvard, Vancouver, ISO, and other styles

19

Bozkurt, Kürşat A., Burak Uzel, Canan Akman, Mustafa Özgüroğlu, and Nil Molinas Mandel. "Intrathoracic Extravasation of Antineoplastic Agents." American Journal of Clinical Oncology 26, no. 2 (2003): 121–23. http://dx.doi.org/10.1097/00000421-200304000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Shahab, Nasir, Syed Haider, and Donald C. Doll. "Vascular Toxicity of Antineoplastic Agents." Seminars in Oncology 33, no. 1 (2006): 121–38. http://dx.doi.org/10.1053/j.seminoncol.2005.11.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Fortner, Clarence L., and Paul J. Vilk. "Aspects of Investigational Antineoplastic Agents." Journal of Pharmacy Practice 4, no. 1 (1991): 64–71. http://dx.doi.org/10.1177/089719009100400107.

Full text

Abstract:

Investigational drugs are regulated by the Food and Drug Administration (FDA) and are not available for widespread patient use. They are screened and evaluated extensively before they are administered to humans in clinical trials. The clinical development process is divided into three phases: phase I, II, and III. Protocols for the investigational agent in each of these phases must be approved by an institutional review board and the patient must be informed of the risks of the study and sign an informed consent document. Once adequate clinical data are collected and analyzed, the information

APA, Harvard, Vancouver, ISO, and other styles

22

Chitambar, Christopher R. "Gallium compounds as antineoplastic agents." Current Opinion in Oncology 16, no. 6 (2004): 547–52. http://dx.doi.org/10.1097/01.cco.0000142071.22226.d2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Hamnvik, O. P. R., P. R. Larsen, and E. Marqusee. "Thyroid Dysfunction from Antineoplastic Agents." JNCI Journal of the National Cancer Institute 103, no. 21 (2011): 1572–87. http://dx.doi.org/10.1093/jnci/djr373.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Grangé, Steven, and Paul Coppo. "Thrombotic microangiopathies and antineoplastic agents." Néphrologie & Thérapeutique 13 (April 2017): S109—S113. http://dx.doi.org/10.1016/j.nephro.2017.01.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 606. The Betulastatins." Journal of Natural Products 81, no. 3 (2018): 458–64. http://dx.doi.org/10.1021/acs.jnatprod.7b00536.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 607. Emetine Auristatins." Journal of Natural Products 83, no. 5 (2020): 1571–76. http://dx.doi.org/10.1021/acs.jnatprod.0c00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Pettit, G. R., S. B. Singh, A. Goswami, and R. A. Nieman. "Antineoplastic agents 157. Quassia kerstingII1." Tetrahedron 44, no. 11 (1988): 3349–54. http://dx.doi.org/10.1016/s0040-4020(01)85969-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Pettit, George R., Venkatswamy Gaddamidi, Delbert L. Herald, et al. "Antineoplastic Agents, 120. Pancratium littorale." Journal of Natural Products 49, no. 6 (1986): 995–1002. http://dx.doi.org/10.1021/np50048a005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Pettit, George R., Gordon M. Cragg, Sheo Bux Singh, James A. Duke, and Dennis L. Doubek. "Antineoplastic Agents, 162. Zephyranthes candida." Journal of Natural Products 53, no. 1 (1990): 176–78. http://dx.doi.org/10.1021/np50067a026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Rogers, Bonnie. "Antineoplastic Agents Action and Toxicities." AAOHN Journal 34, no. 11 (1986): 530–38. http://dx.doi.org/10.1177/216507998603401104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bodet, C. A., J. H. Jorgensen, and D. J. Drutz. "Antibacterial activities of antineoplastic agents." Antimicrobial Agents and Chemotherapy 28, no. 3 (1985): 437–39. http://dx.doi.org/10.1128/aac.28.3.437.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Pettit, George R., Noeleen Melody, Michael Simpson, Michael Thompson, Delbert L. Herald, and John C. Knight. "Antineoplastic Agents 500. Narcistatin†,1." Journal of Natural Products 66, no. 1 (2003): 92–96. http://dx.doi.org/10.1021/np020225i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Bozkurt, Kürşat A., Burak Uzel, Canan Akman, Mustafa Özgüroğlu, and Nil Molinas Mandel. "Intrathoracic Extravasation of Antineoplastic Agents." American Journal of Clinical Oncology 26, no. 2 (2003): 121–23. http://dx.doi.org/10.1097/01.coc.0000017088.74592.96.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Borch, Richard F., and Thomas J. Montine. "Renal toxicity of antineoplastic agents." Toxicology Letters 53, no. 1-2 (1990): 93–96. http://dx.doi.org/10.1016/0378-4274(90)90100-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Weiss, Raymond B., and James R. Baker. "Hypersensitivity reactions from antineoplastic agents." Cancer and Metastasis Reviews 6, no. 3 (1987): 413–32. http://dx.doi.org/10.1007/bf00144273.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Hall, Amy L., Paul A. Demers, George Astrakianakis, Calvin Ge, and Cheryl E. Peters. "Estimating National-Level Exposure to Antineoplastic Agents in the Workplace: CAREX Canada Findings and Future Research Needs." Annals of Work Exposures and Health 61, no. 6 (2017): 656–58. http://dx.doi.org/10.1093/annweh/wxx042.

Full text

Abstract:

AbstractObjectives:Occupational exposure to antineoplastic agents occurs in various environments and is associated with increased cancer risk and adverse reproductive outcomes. National-level information describing the location and extent of occupational exposure to antineoplastic agents is unavailable in Canada and most other countries. CAREX Canada aimed to estimate the prevalence and relative levels of occupational exposures to antineoplastic agents across work setting, occupation, and sex.Methods:‘Exposure’ was defined as any potential for worker contact with antineoplastic agents. Baselin

APA, Harvard, Vancouver, ISO, and other styles

37

Hamazaki, Risa, and Yoshihiro Uesawa. "Characterization of Antineoplastic Agents Inducing Taste and Smell Disorders Using the FAERS Database." Pharmaceuticals 17, no. 9 (2024): 1116. http://dx.doi.org/10.3390/ph17091116.

Full text

Abstract:

Taste and smell disorders can worsen the nutritional status of patients receiving chemotherapy and potentially affect drug treatment. However, there is limited knowledge on antineoplastic agents that induce taste and smell disorders. Therefore, we used the U.S. Food and Drug Administration Adverse Event Reporting System database to analyze the characteristics of patients and antineoplastic agents in relation to taste and smell disorders. No gender differences related to the onset of taste and smell disorders were found, whereas older age was identified as a possible risk factor. Among the anti

APA, Harvard, Vancouver, ISO, and other styles

38

Mary Philip, Sherin, Joji Johnson, Litha Johnson, and Bharath Rangarajan. "A Review on Antineoplastic Agents Induced Toxicities and its Managements." International Journal of Science and Research (IJSR) 10, no. 8 (2021): 1005–12. https://doi.org/10.21275/sr21818165637.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Chen, Rong. "A Pharmacovigilance Study of the Association between Antineoplastic Agents and Neutropenia Adverse Events Based on Food and Drug Administration Adverse Event Reporting System Data." Toxicology: Current Research 8, no. 1 (2024): 1–8. http://dx.doi.org/10.24966/tcr-3735/100029.

Full text

Abstract:

Neutropenia is one of the most common adverse events associated with antineoplastic agents. However, comprehensive real-world studies on the relationship between antineoplastic agents and neutropenia are relatively scarce.

APA, Harvard, Vancouver, ISO, and other styles

40

Johnson, Candace S. "Modulation of chemotherapy antineoplastic agents with biologic agents." Current Opinion in Oncology 4, no. 6 (1992): 1108. http://dx.doi.org/10.1097/00001622-199212000-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Zhang, Hai-Long, and Yiqian Li. "Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis." Pharmaceutical Patent Analyst 10, no. 2 (2021): 73–82. http://dx.doi.org/10.4155/ppa-2021-0004.

Full text

Abstract:

Osteoporosis and cancer are becoming a major public health problem. Some studies have shown that osteoporosis drugs may have anti-cancer effects. To better understand the relationship between drugs for osteoporosis and antineoplastic agents, and to better demonstrate recent developments for patents concerning drugs for osteoporosis, we conducted an analysis of US patents. The results indicated that there was a good correlation between agents for osteoporosis and antineoplastic agents, which indicated that numerous anti-osteoporosis agents displayed antineoplastic activities. Our study was the

APA, Harvard, Vancouver, ISO, and other styles

42

Beckwith, M. Christina, and Linda S. Tyler. "Preventing Medication Errors with Antineoplastic Agents, Part 1." Hospital Pharmacy 35, no. 5 (2000): 511–26. http://dx.doi.org/10.1177/001857870003500502.

Full text

Abstract:

Goal — The goal of this program is to present practical ways to prevent medication errors with antineoplastic agents, identify common types of medication errors, and describe a system for reducing the incidence of medication errors and responding appropriately to antineoplastic medication errors. Objectives — At the completion of this program, the participant will be able to: 1. Describe the scope and impact of medication errors 2. Define common terms used in medication error literature. 3. List four common types of prescribing errors made with anti-neoplastic agents. 4. Identify steps where m

APA, Harvard, Vancouver, ISO, and other styles

43

Boschi, Rita, and Elena Rostagno. "Extravasation of antineoplastic agents: prevention and treatments." Pediatric Reports 4, no. 3 (2012): 28. http://dx.doi.org/10.4081/pr.2012.e28.

Full text

Abstract:

The extravasation of antineoplastic agents is an unwanted and distressing situation that can easily occur. It may cause severe and irreversible local injuries. Left untreated, vesicant chemotherapy extravasation can potentially cause tissue necrosis, functional impairment and permanent disfigurement. This article provides a review of current literature regarding recommendations on the prevention and treatment of extravasation of antineoplastic agents.

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Antineoplastic agents can cause allergic reactions." Reactions Weekly &NA;, no. 428 (1992): 4. http://dx.doi.org/10.2165/00128415-199204280-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Pharmacokinetic drug interactions with antineoplastic agents." Drugs & Therapy Perspectives 5, no. 9 (1995): 12–14. http://dx.doi.org/10.2165/00042310-199505090-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

BATRA, JANENDRA K., CHII M. LIN, ERNEST HAMEL, LEONARD JURD, and LARRY J. POWERS. "New Antineoplastic Agents with Antitubulin Activity." Annals of the New York Academy of Sciences 466, no. 1 Dynamic Aspec (1986): 785–87. http://dx.doi.org/10.1111/j.1749-6632.1986.tb38459.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

McDiarmid, Melissa, and Thomas Egan. "Acute Occupational Exposure to Antineoplastic Agents." Journal of Occupational and Environmental Medicine 30, no. 12 (1988): 984–87. http://dx.doi.org/10.1097/00043764-198812000-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Dimopoulou, I., A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos. "Pulmonary toxicity from novel antineoplastic agents." Annals of Oncology 17, no. 3 (2006): 372–79. http://dx.doi.org/10.1093/annonc/mdj057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Delitheos, A., I. Karavokyros, and E. Tiligada. "Response ofSaccharomyces cerevisiaestrains to antineoplastic agents." Journal of Applied Bacteriology 79, no. 4 (1995): 379–83. http://dx.doi.org/10.1111/j.1365-2672.1995.tb03151.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Phillips, Nancy C. "The Safe Handling of Antineoplastic Agents." Journal of Pharmacy Technology 1, no. 1 (1985): 19–24. http://dx.doi.org/10.1177/875512258500100108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!